Key result
919 syrup decreases body weight in NAFLD rats by reversing abnormal Ghrelin pathway expression.
Why the study?
Although 919 syrup may effectively treat NAFLD in rats, its potential toxicity and specific regulatory mechanisms required further exploration.
Does 919 syrup improve Ghrelin pathway gene expression and intestinal microbiota in rats with NAFLD without causing toxicity?
Does 919 syrup improve Ghrelin pathway gene expression and intestinal microbiota in rats with NAFLD without causing toxicity?
p-value: p=<0.05
919 syrup appears to be a safe therapeutic option that regulates the Ghrelin pathway and intestinal microbiota in a rat model of NAFLD.
Hypothesis-generating in rat NAFLD; leaves open human translation and clinical utility.
As a manifestation of metabolic syndrome in the liver, non-alcoholic fatty liver disease (NAFLD) has become the top cause of liver disease in many countries. Recent studies have shown that intestinal microbiota disorder plays an important role in the occurrence and development of NAFLD and that regulating intestinal microbiota provides a new option for NAFLD treatment. In addition, research indicates that risk of NAFLD increases as body mass index rises, and interventions that reduce body weight and change diet can help to lower the incidence of NAFLD. Studies have found that 919 syrup may effectively treat NAFLD in rats by improving liver function and lipid metabolism and regulating body weight and feed intake, however, its potential toxicity and the specific mechanism by which it controls this disease require further exploration. This study assesses both the toxicity of 919 syrup and its regulatory effect on the appetite-related Ghrelin pathway and intestinal microbiota of rats with NAFLD. Results indicate that 919 syrup has no obvious side-effects on body weight, feed intake, blood glucose level, hepatorenal function, and liver tissue structure of normal rats. Moreover, 919 syrup can reverse abnormal changes to expression of Ghrelin pathway genes related to appetite in both the brain and stomach and repair alterations to the intestinal microbiota in rats with NAFLD. This herbal medicine is a safe and promising therapeutic drug for the treatment of NAFLD.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) studied Non-alcoholic fatty liver disease (n=50). 919 syrup vs. Normal saline was evaluated on Body weight and feed intake (p=<0.05). 919 syrup significantly decreased body weight and feed intake, reversed abnormal Ghrelin pathway gene expression, and restored intestinal microbiota diversity in rats with non-alcoholic fatty liver disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: